Organigram Holdings Inc. (TSE:OGI - Free Report) - Equities research analysts at Atb Cap Markets dropped their FY2025 earnings per share estimates for Organigram in a research report issued on Monday, December 16th. Atb Cap Markets analyst F. Gomes now anticipates that the company will earn ($0.13) per share for the year, down from their prior forecast of ($0.12). The consensus estimate for Organigram's current full-year earnings is $0.16 per share.
A number of other equities research analysts also recently commented on the stock. ATB Capital cut their target price on shares of Organigram from C$5.25 to C$3.50 in a research report on Tuesday. Canaccord Genuity Group reduced their target price on shares of Organigram from C$3.60 to C$3.15 and set a "speculative buy" rating for the company in a report on Monday, December 9th.
Check Out Our Latest Stock Analysis on Organigram
OGI traded up C$0.10 during midday trading on Thursday, hitting C$2.20. 71,111 shares of the company traded hands, compared to its average volume of 295,383. The company's 50-day moving average is C$2.26 and its 200 day moving average is C$2.30. Organigram has a 52 week low of C$1.61 and a 52 week high of C$3.95. The firm has a market capitalization of C$238.85 million, a PE ratio of -0.88, a price-to-earnings-growth ratio of 0.42 and a beta of 1.13. The company has a quick ratio of 2.62, a current ratio of 6.95 and a debt-to-equity ratio of 1.13.
In other Organigram news, Senior Officer Paolo De Luca sold 12,014 shares of the firm's stock in a transaction on Thursday, October 24th. The stock was sold at an average price of C$2.52, for a total transaction of C$30,275.28. Company insiders own 31.32% of the company's stock.
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Organigram, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Organigram wasn't on the list.
While Organigram currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.